Today: 2 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Union Pacific stock price rises 2% as UNP tracks rail rally; merger deadline in focus

Union Pacific stock price rises 2% as UNP tracks rail rally; merger deadline in focus

New York, February 3, 2026, 15:13 — Regular session underway Union Pacific shares climbed roughly 2.2% to $240.34 in Tuesday afternoon trading, bouncing off a session low near $234.16 and hitting a high of $241.87. CSX Corp. advanced about 1.4%, Norfolk Southern Corp. was up close to 2%, while Canadian Pacific Kansas City Limited gained approximately 1.7%.
3 February 2026
·····
Citigroup stock holds up on deal chatter and rate bets as Wall Street slides

Citigroup stock holds up on deal chatter and rate bets as Wall Street slides

NEW YORK, Feb 3, 2026, 15:02 EST — Regular session Shares of Citigroup Inc climbed roughly 0.4% to $116.67 by 2:47 p.m. EST, swinging between $115.42 and $118.90 earlier. The S&P 500 ETF SPY dropped around 1.4%, with the Nasdaq-tracking QQQ sliding about 2.3%. Meanwhile, JPMorgan Chase rose about 1.1%, and Bank of America along with Wells Fargo showed modest gains.
3 February 2026
·
1 … 303 304 305 306 307 … 877

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Go toTop